Juno Therapeutics, Inc., A Bristol-myers Squibb Company

This early-stage study is testing a new CAR T-cell therapy for people with severe autoimmune diseases like lupus, rheumatoid arthritis, and scleroderma that haven't responded to standard treatments. Researchers will collect immune cells from participants, genetically modify them …

This early-stage study is testing the safety and optimal dose of a new cell therapy called BMS-986515 for people with severe autoimmune diseases that haven't responded to standard treatments. The therapy uses modified immune cells from healthy donors that are designed to target a…

This is an early-stage study testing a new type of CAR-T cell therapy, called BMS-986453, for people with multiple myeloma that has come back or stopped responding to other treatments. The main goal is to find a safe dose and understand the side effects of this 'living drug,' whi…

This study is testing a new type of treatment called arlocabtagene autoleucel (BMS-986393), a CAR T-cell therapy, for adults with multiple myeloma that has returned or stopped responding to other treatments. The goal is to see how well this therapy works and how safe it is for pa…

This study is testing whether a new type of personalized immune cell therapy, called arlo-cel, works better than standard treatments for adults with multiple myeloma that has returned or stopped responding to prior therapies, including lenalidomide. Researchers will compare how l…

This study is testing whether a personalized immune cell therapy called liso-cel can effectively treat primary central nervous system lymphoma (a rare brain cancer) as the first treatment for patients who are not eligible for stem cell transplants. The trial will enroll 65 adults…

This study is testing an experimental one-time treatment called CC-97540 for people with active systemic lupus erythematosus (SLE), including lupus affecting the kidneys. The treatment involves collecting and genetically modifying a patient's own immune cells (CAR T-cells) to tar…

This early-stage study is testing whether a modified immune cell therapy called CC-97540 is safe for people with multiple sclerosis or myasthenia gravis. The treatment uses specially engineered T-cells that target CD19, a protein on certain immune cells thought to drive these aut…

This early-stage study is testing a new type of personalized immune cell therapy (called arlocabtagene autoleucel) when given alongside other investigational drugs. It aims to find safe doses and see if these combinations can help control multiple myeloma that has returned or sto…